These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38804790)

  • 1. Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
    Jiang R; Han B; Xu W; Zhang X; Peng C; Dang Q; Sun W; Lin L; Lin Y; Fan L; Lv D; Shao L; Chen Y; Qiu Y; Han L; Kong W; Li G; Wang K; Peng J; Lin B; Tong Z; Lu X; Wang L; Gao F; Feng J; Li Y; Ma X; Wang J; Wang S; Shen W; Wang C; Yan K; Lin Z; Jin C; Mao L; Liu J; Kushnareva Y; Kotoi O; Zhu Z; Royal M; Brunswick M; Ji H; Xu X; Lu H
    NEJM Evid; 2024 Jun; 3(6):EVIDoa2400026. PubMed ID: 38804790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
    Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
    Med; 2024 Jan; 5(1):42-61.e23. PubMed ID: 38181791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    Cao B; Wang Y; Lu H; Huang C; Yang Y; Shang L; Chen Z; Jiang R; Liu Y; Lin L; Peng P; Wang F; Gong F; Hu H; Cheng C; Yao X; Ye X; Zhou H; Shen Y; Liu C; Wang C; Yi Z; Hu B; Xu J; Gu X; Shen J; Xu Y; Zhang L; Fan J; Tang R; Wang C
    N Engl J Med; 2024 Jan; 390(3):230-241. PubMed ID: 38231624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
    Caraco Y; Crofoot GE; Moncada PA; Galustyan AN; Musungaie DB; Payne B; Kovalchuk E; Gonzalez A; Brown ML; Williams-Diaz A; Gao W; Strizki JM; Grobler J; Du J; Assaid CA; Paschke A; Butterton JR; Johnson MG; De Anda C
    NEJM Evid; 2022 Feb; 1(2):EVIDoa2100043. PubMed ID: 38319179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
    Feld JJ; Kandel C; Biondi MJ; Kozak RA; Zahoor MA; Lemieux C; Borgia SM; Boggild AK; Powis J; McCready J; Tan DHS; Chan T; Coburn B; Kumar D; Humar A; Chan A; O'Neil B; Noureldin S; Booth J; Hong R; Smookler D; Aleyadeh W; Patel A; Barber B; Casey J; Hiebert R; Mistry H; Choong I; Hislop C; Santer DM; Lorne Tyrrell D; Glenn JS; Gehring AJ; Janssen HLA; Hansen BE
    Lancet Respir Med; 2021 May; 9(5):498-510. PubMed ID: 33556319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
    Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
    JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
    Arribas JR; Bhagani S; Lobo SM; Khaertynova I; Mateu L; Fishchuk R; Park WY; Hussein K; Kim SW; Ghosn J; Brown ML; Zhang Y; Gao W; Assaid C; Grobler JA; Strizki J; Vesnesky M; Paschke A; Butterton JR; De Anda C
    NEJM Evid; 2022 Feb; 1(2):EVIDoa2100044. PubMed ID: 38319178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.